Use of aspirin, Non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), And risk of psoriasis and psoriatic arthritis: A cohort study

Acta Dermato-Venereologica

Volumn 95, Issue 2, 2015, Pages 217-222

  Wu, Shaowei ^a   Han, Jiali ^a,b,c   Qureshi, Abrar A ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INDIANA UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Acetaminophen; Aspirin; Inflammation; Non steroidal anti inflammatory drugs; Psoriasis; Psoriatic arthritis

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ANALGESIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RISK ASSESSMENT; SCREENING; ARTHRITIS, PSORIATIC; CHEMICALLY INDUCED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; TIME; UNITED STATES;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; ASPIRIN; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSORIASIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84928259517     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1855     Document Type: Article

References (50)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–371.
2. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899–1912.
3. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 1987; 62: 127–141.
4. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573–577.
5. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009; 5: 83–91.
6. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850–860.
7. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999; 107: 27S–35S.
8. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006; 79: 9–19.
9. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008; 22: 383–390.
10. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 2002; 6: 449–459.
11. Meyerhoff JO. Exacerbation of psoriasis with meclofenamate. N Engl J Med 1983; 5: 309–496.
12. Ben-Chetrit E, Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis 1986; 38: 45.
13. Ellis CN, Fallon JD, Kang S, Vanderveen EE, Voorhees JJ. Topical application of nonsteroidal anti-inflammatory drugs prevents vehicle-induced improvement of psoriasis. J Am Acad Dermatol 1986; 14: 39–43.
14. Powles AV, Griffiths CEM, Seifert MH, Fry L. Exacerbation of psoriasis by indomethacin. Br J Dermatol 1987; 117: 799–800.
15. Lazarova AZ, Tsankov NK, Zlatkov NB. Psoriasis induced by topically applied indomethacin. Clin Exp Dermatol 1989; 14: 2601.
16. Clark DW, Coulter DM. Psoriasis associated with rofecoxib. Arch Dermatol 2003; 139: 1223.
17. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: casecontrol and case-crossover studies. Acta Derm Venereol 2005; 85: 299–303.
18. Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fuchs CS, et al. Aspirin, nonsteroidal antiinflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012; 156: 350–359.
19. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol 1990; 85: 962–963.
20. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol 1982; 106: 323–330.
21. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis 2013; 72: 1200–1205.
22. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol 2003; 48: 805–821.
23. Dominguez PL, Assarpour A, Kuo H, Holt EW, Tyler S, Qureshi AA. Development and pilot-testing of a psoriasis screening tool. Br J Dermatol 2009; 161: 778–784.
24. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581–587.
25. Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 2009; 301: 573–579.
26. Wu S, Li WQ, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheum 2014; 66: 304–310.
27. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914–923.
28. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med 2007; 167: 562–572.
29. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426–433.
30. Fearon U, Veale DJ. Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001; 26: 333–337.
31. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 2007; 7: 311–340.
32. Martínez-González J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007; 13: 2215–2227.
33. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196–202.
34. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 85–87.
35. Lubrano E, Scarpa R. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2012; 64: 107–112.
36. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64: ii74–77.
37. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71: 319–326.
38. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19: S17–S20.
39. Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury C, et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985; 44: 189–193.
40. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274–2282.
41. Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum 2007; 37: 164–173.
42. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606–615.
43. Higgs GA, Eakins KE, Mugridge KG, Moncada S, Vane J. The effects of non-steroidal anti-inflammatory drugs on leukocyte migration in carrageenin induced inflammation. Eur J Pharmacol 1980; 66: 6681–6686.
44. Davies DM, Ferner RE, de Glanville Heds. Davies’s textbook of adverse drug reactions. 5th ed. London, England: Chapman & Hall 1998; 566–584.
45. Woodbury DM, Fingl E. Analgesic-antipyretics, antiinflammatory agents, and drugs employed in the therapy of gout. In: Goodman LS and Gilman A, editors. The Pharmacological Basis of Therapeutics (Fifth Edition). New York: Macmillan, 1975, p. 325.
46. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107: 1170–1184.
47. Ulrych T, Böhm A, Polzin A, Daum G, Nüsing RM, Geisslinger G, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011; 9: 790–798.
48. Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736–740.
49. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012; 71: 1267–1272.
50. Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012; 71: 804–808.